Building Biopharma Resilience — Cytiva’s Pierre-Alain Ruffieux on Balancing Progress and Preparedness

Resilience is no longer a corporate slogan — it’s the new currency of survival in biopharma. As the sector races between scientific breakthroug...

October 17, 2025 | Friday | Interaction
Kezar Life Sciences Initiates Strategic Review Following FDA Setback on Autoimmune Hepatitis Trial

-Kezar Life Sciences, Inc. a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated di...

October 17, 2025 | Friday | News
Roquette Opens Health & Pharma Solutions Innovation Centre in Brazil to Drive Drug Delivery Innovation and Inspire Future Scientists

Roquette, a global leader in plant-based ingredients and pharmaceutical excipients for health, nutrition and bio industrial markets,  celebrates the...

October 17, 2025 | Friday | News
French Biotech EVerZom Raises €10 Million to Launch First Clinical Trial of Exosome Therapy EVerGel™

Through this funding round, the company will initiate the clinical development of its first therapeutic candidate, EVerGel, in 2026, and will enhance its...

October 16, 2025 | Thursday | News
NuCana’s NUC-3373 Plus Pembrolizumab Shows Durable Responses in Heavily Pre-Treated Cancer Patients

NUC-3373 Plus Pembrolizumab Continues to Show Favorable Efficacy and Safety Profile in Heavily Pre-treated Patients Latest Data Cut-Off Shows Patient wi...

October 16, 2025 | Thursday | News
Corventum Secures FDA Clearance for IND of CVT-130 to Prevent Chemotherapy-Induced Cardiotoxicity

-Corventum, Inc., a new medicines company advancing novel therapies to make existing cancer treatments safer and more effective,  announced the clea...

October 15, 2025 | Wednesday | News
Daiichi Sankyo Showcases Transformative ADC Data at ESMO 2025

Back-to-back Presidential Symposium presentations of ENHERTU from DESTINY-Breast11 and DESTINY-Breast05 demonstrate its potential to become a foundat...

October 14, 2025 | Tuesday | News
Excellergy Launches with $70M Series A to Redefine Allergy Treatment with First-in-Class Trifunctional ECRIs

-Redefining Allergy Treatment with New Class of Trifunctional ECRIs designed to deliver powerful efficacy, rapid relief and complete control of alle...

October 14, 2025 | Tuesday | News
Gelteq Partners with Melbourne Health to Develop Innovative Oral Gel Product for Bowel Polyp Prevention

Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solution...

October 10, 2025 | Friday | News
Beghou Launches Arc Platform to Redefine Life Sciences Commercialization with Composable Intelligence

Beghou announces the Beghou Arc Platform, a flexible, connected commercialization platform designed to help life sciences teams overcome data overload, r...

October 10, 2025 | Friday | News
Zenas BioPharma Secures Global Rights to Orelabrutinib, Expands Pipeline with Novel IL-17AA/AF and TYK2 Inhibitors

Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO) and InnoCare Pharma Limited (&ldqu...

October 09, 2025 | Thursday | News
Lupin’s €190 Million Vision: Thierry Volle on Building a Global Ophthalmology Powerhouse

The €190 million acquisition of VISUfarma marks a pivotal moment in Lupin’s transformation into a global specialty-led biopharma. With VISUfarma...

October 08, 2025 | Wednesday | Interaction
Draig Therapeutics Secures FDA Clearance to Launch Phase 2 Trial of DT-101 for Major Depressive Disorder

DT-101 is designed to allow effective modulation of the AMPA receptor without compromising safety Phase 2 clinical trial initiation anticipated before...

October 03, 2025 | Friday | News
George Medicines and Biolab Partner to Bring Innovative Hypertension Therapy GMRx2 to Brazil

Biolab Farmacêutica gains exclusive rights in Brazil to GMRx2, an innovative single pill combination of three medicines, including two doses that...

October 03, 2025 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close